Peptide Half-Life, Explained: Why Dosing Frequency Varies
Native GLP-1 lasts ~2 minutes; semaglutide lasts ~1 week. Half-life is the hidden variable behind every dosing schedule.
Two peptides can target the same receptor and still call for wildly different dosing — one daily, another weekly. The usual explanation is a single property: half-life, the time it takes for the body to clear roughly half of a dose from circulation. Understanding it demystifies why some schedules look the way they do, and why you cannot simply move a dose around for convenience.
What half-life actually measures
Half-life describes the rate of decline of a compound’s concentration in the blood. After one half-life, about half remains; after two, about a quarter; and so on. A peptide with a short half-life rises and falls quickly, so keeping it in an effective range may require frequent dosing. A long half-life means the compound lingers, allowing infrequent doses to maintain a relatively steady level.
The key idea: dosing frequency is mostly an attempt to keep concentration inside a useful window — high enough to act, not so high that side effects dominate. Half-life sets how hard that is to do.
Why peptides differ so much: the GLP-1 family
The GLP-1 system is the clearest worked example. Native GLP-1 has a half-life of about 2 minutes, because enzymes — primarily dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase — degrade it almost immediately. That makes the natural hormone useless as a drug.
Drug designers extend half-life deliberately, and the GLP-1 receptor agonists show each trick and its payoff:
| Compound | Approx. half-life | Engineering |
|---|---|---|
| Native GLP-1 | ~2 minutes | none (rapidly cleaved by DPP-4) |
| Exenatide | ~2–4 hours | Gly⁸ substitution resists DPP-4 |
| Liraglutide | ~13 hours | fatty-acid acylation → albumin binding |
| Semaglutide | ~7 days (1 week) | acylation + Aib⁸ substitution blocking DPP-4 |
Semaglutide’s ~1-week half-life comes from a C18 fatty-diacid chain that reversibly binds serum albumin (riding albumin’s slow turnover) plus an Aib⁸ substitution that sterically blocks DPP-4. That is precisely why it can be dosed once weekly rather than daily.
What this means in practice
A few consequences follow directly from the pharmacology:
- Short half-life, frequent dosing. Skipping a dose causes a real trough.
- Long half-life, steadier levels. More forgiving of timing, but slower to clear if a problem arises. With a ~1-week half-life, semaglutide takes roughly 5 weeks (about five half-lives) to wash out after the last dose.
- Steady state takes time. Levels typically plateau after roughly four to five half-lives of consistent dosing.
This last point explains why effects — and some side effects — can keep evolving for weeks after starting.
The takeaway
Dosing frequency is not arbitrary and rarely flexible. It is engineered around half-life to hold a compound in its effective range. The GLP-1 family makes the point cleanly: the same receptor, dosed anywhere from continuously (native, ~2 minutes) to once weekly (semaglutide, ~1 week), purely because of how each molecule resists degradation. If a schedule seems oddly specific, half-life is usually the reason — and that is a feature, not red tape.